How does KLOW differ from GLOW?

KLOW adds KPV, an anti-inflammatory tripeptide, to the GLOW trio of BPC-157, TB-500, and GHK-Cu, broadening the blend toward inflammation control and gut healing.

What does the KPV component do?

KPV is the C-terminal fragment of alpha-MSH and is studied for its ability to inhibit NF-kB and pro-inflammatory cytokines, including in the intestinal lining.

Is KLOW approved for human use?

No. All four components are unapproved research peptides sold strictly for laboratory study.

← All peptides

Healing & Recovery

Collagen & Skin

Research Chemical

KLOW Blend (BPC-157, TB-500, KPV, GHK-Cu)

Also known as: Klow Blend, KLOW, BPC-157, TB-500, KPV, GHK-Cu Blend

KLOW extends the GLOW concept by adding the anti-inflammatory tripeptide KPV to BPC-157, TB-500, and GHK-Cu. It is studied for recovery, gut and tissue healing, and skin quality, and its components are unapproved research peptides.

Mechanism of Action

KLOW combines four peptides with complementary repair and anti-inflammatory actions. BPC-157 promotes VEGFR2- and nitric-oxide-driven angiogenesis and fibroblast migration; TB-500 sequesters G-actin to accelerate cell migration, vascularization, and wound closure; GHK-Cu stimulates collagen, elastin, and glycosaminoglycan synthesis and tissue-remodeling gene expression. KPV, the C-terminal tripeptide of alpha-MSH, exerts potent anti-inflammatory effects by inhibiting NF-kB and pro-inflammatory cytokine signaling, including in intestinal epithelium. Together the blend targets angiogenesis, matrix repair, and inflammation control simultaneously.

Half-life: Component-dependent: BPC-157, KPV, and GHK-Cu are short (minutes to hours), TB-500 functionally longer (days)
Administration Routes: subcutaneous
Research Status: Research Chemical